Trials / Active Not Recruiting
Active Not RecruitingNCT07011706
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ATI-045 in Patients With Moderate-to-Severe Atopic Dermatitis
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 110 (actual)
- Sponsor
- Aclaris Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.
Detailed description
A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ATI-045 in Patients with Moderate-to-Severe Atopic Dermatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ATI-045 | ATI-045 group |
| DRUG | Placebo | Placebo group |
Timeline
- Start date
- 2025-05-30
- Primary completion
- 2026-08-01
- Completion
- 2026-10-01
- First posted
- 2025-06-10
- Last updated
- 2026-03-25
Locations
60 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07011706. Inclusion in this directory is not an endorsement.